Teads Holding Co. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Teads Holding Co. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $889.88M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $935.82M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $992.08M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $1.02B | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $767.14M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $687.33M | Mar 18, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $429.05M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $192.10M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $184.80M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $192.65M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $240.26M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $165.06M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $141.79M | Mar 18, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($517.07M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($711.0K) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $10.24M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($24.58M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $11.00M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $4.36M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($20.51M) | Mar 18, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($399.02M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($12.64M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($8.64M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($13.55M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $34.56M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $10.18M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($14.59M) | Mar 18, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.55M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $37.01M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $35.98M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $40.32M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $39.17M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $28.96M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $26.39M | Mar 18, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.61M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $68.56M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $13.75M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $3.81M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $56.76M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $52.99M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $16.74M | Mar 18, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.61M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $7.38M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $10.13M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $13.38M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $9.74M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.51M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $2.45M | Mar 18, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $549.21M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $664.64M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $781.15M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $795.89M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $356.49M | Mar 18, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23B | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $317.87M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $441.57M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $563.36M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $539.12M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $273.86M | Mar 18, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.44M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $231.34M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $223.06M | Mar 16, 2026 |
| FY2025 | Dec 31, 2022 | $217.79M | Mar 16, 2026 |
| FY2024 | Dec 31, 2021 | $256.78M | Mar 7, 2025 |
| FY2023 | Dec 31, 2020 | ($79.81M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2019 | ($89.66M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2018 | ($112.53M) | Mar 18, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.99M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $63.06M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $63.06M | Mar 16, 2026 |
| FY2023 | Dec 31, 2022 | $63.06M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $32.88M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $32.88M | Mar 15, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($686.56M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($169.49M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($168.78M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($179.02M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($157.25M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($168.25M) | Mar 18, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.22M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $89.09M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $70.89M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $105.58M | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | $455.40M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $93.64M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $49.59M | Mar 18, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $605.11M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $118.00M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $236.00M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $236.00M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 18, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 18, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 18, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 95.98M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 50.09M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 49.73M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 52.23M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 56.70M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 17.16M | Mar 18, 2022 |